Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis.
Publication
, Journal Article
Moseley, RP; Davies, AG; Richardson, RB; Zalutsky, M; Carrell, S; Fabre, J; Slack, N; Bullimore, J; Pizer, B; Papanastassiou, V
Published in: Br J Cancer
October 1990
Fifteen patients with neoplastic meningitis received a single intrathecal injection of between 11 and 60 mCi of a 131I radiolabelled monoclonal antibody (MoAb), chosen for its immunoreactivity to tumour. Major toxicity was manifest as nausea, vomiting and headache (7/15 patients), reversible bone marrow suppression (3/8 patients) and seizures (2/15 patients). Nine patients were evaluable for either a tumour or clinical response. Six of these demonstrated an event-free response that was maintained for periods of between 7 and 26 months.
Duke Scholars
Published In
Br J Cancer
DOI
ISSN
0007-0920
Publication Date
October 1990
Volume
62
Issue
4
Start / End Page
637 / 642
Location
England
Related Subject Headings
- Survival Rate
- Pilot Projects
- Oncology & Carcinogenesis
- Meningitis
- Meningeal Neoplasms
- Iodine Radioisotopes
- Injections, Spinal
- Humans
- Cause of Death
- Bone Marrow
Citation
APA
Chicago
ICMJE
MLA
NLM
Moseley, R. P., Davies, A. G., Richardson, R. B., Zalutsky, M., Carrell, S., Fabre, J., … Papanastassiou, V. (1990). Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis. Br J Cancer, 62(4), 637–642. https://doi.org/10.1038/bjc.1990.345
Moseley, R. P., A. G. Davies, R. B. Richardson, M. Zalutsky, S. Carrell, J. Fabre, N. Slack, J. Bullimore, B. Pizer, and V. Papanastassiou. “Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis.” Br J Cancer 62, no. 4 (October 1990): 637–42. https://doi.org/10.1038/bjc.1990.345.
Moseley RP, Davies AG, Richardson RB, Zalutsky M, Carrell S, Fabre J, et al. Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis. Br J Cancer. 1990 Oct;62(4):637–42.
Moseley, R. P., et al. “Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis.” Br J Cancer, vol. 62, no. 4, Oct. 1990, pp. 637–42. Pubmed, doi:10.1038/bjc.1990.345.
Moseley RP, Davies AG, Richardson RB, Zalutsky M, Carrell S, Fabre J, Slack N, Bullimore J, Pizer B, Papanastassiou V. Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis. Br J Cancer. 1990 Oct;62(4):637–642.
Published In
Br J Cancer
DOI
ISSN
0007-0920
Publication Date
October 1990
Volume
62
Issue
4
Start / End Page
637 / 642
Location
England
Related Subject Headings
- Survival Rate
- Pilot Projects
- Oncology & Carcinogenesis
- Meningitis
- Meningeal Neoplasms
- Iodine Radioisotopes
- Injections, Spinal
- Humans
- Cause of Death
- Bone Marrow